Non-peptide ligands for bradykinin receptors 1995 – 2004

Bibliography

• BURKE JE, CHERONIS JC, WHALLEY ET: Bradykinin receptor antagonists. Expert Opin. Ther. Patents (1995) 5:331–340.
   Google Scholar
• •Provides an analysis of the BK area for the preceding period, and references therein.
   Google Scholar
• STEWART JM, GERA L, YORK EJ, CT-JAN DC, BUNN P: Bradykinin antagonists: present progress and future prospects. Immunopharmacology (1999) 43:155–161.
   PubMedGoogle Scholar
• •Useful overview of the activities in the BK peptide field.
   Google Scholar
• BHOOLA KD, FIGUEROA CD, WORTHY K: Bioregulation of kinins: kallikreins, kininogens and kininases. PharmacoL Rev. (1992) 44:1–80.
   PubMed Web of Science ®Google Scholar
• CASSIM B, MODY G, BHOOLA KD: Kallikrein cascade and cytokines in inflamed joints. PharmacoL Ther. (2002) 92:1–34.
   Google Scholar
• STEWART JM: Bradykinin antagonists: development and applications. Biopolymers (1995) 37:143–155.
   PubMed Web of Science ®Google Scholar
• KOZIK A. MOORE RB, POTEMPA J, IMAMURA T, RAPALA-KOZIK M, TRAVIS J: A novel mechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. Biol. Chem. (1998) 273:33224–33229.
   Google Scholar
• CARRETERO OA, SCICLI AG: The renal kallikrein-kinin system. Am. J. PhysioL (1980) 238:F247–F255.
   PubMed Web of Science ®Google Scholar
• REGOLI D, BARABÉ J: Pharmacology of bradykinin and related kinins. PharmacoL Rev. (1980) 32:1–46.
   PubMed Web of Science ®Google Scholar
• MARCEAU F: Kinin B1 receptors: a review. Immunopharmacology (1995) 30:1–26.
   Google Scholar
• MARCEAU F: Kinin B1 receptor induction and inflammation. In: The Kinin System. Farmer SG (Ed.), Academic Press, London (1997):43–156.
   Google Scholar
• WOTHERSPOON G, WINTER J: Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system. Neurosci. Lett. (2000) 294:175–178.
   PubMed Web of Science ®Google Scholar
• BOELS K, SCHALLER HC: Identification and characterisation of GPR100 as a novel human G-protein-coupled bradykinin receptor. Br. J. PharmacoL (2003) 140:932–938.
   PubMed Web of Science ®Google Scholar
• LIU C, CHEN J, SUTTON S et al.: Identification of Relaxin-3/INSL7 as a ligand for GPCR142. J. Biol. Chem. (2003) 278:50765–50770.
   Google Scholar
• LEEB-LUNDBERG LMF: Bradykinin specificity and signaling at GPR100 and B2 kinin receptors. Br. J. PharmacoL (2004) 143:931–932.
   Google Scholar
• MEINI S, BELLUCCI F, CUCCHI P et al.:Bradykinin B2 and GPR100 receptors: a paradigm for receptor signal transduction pharmacology. Br. J. PharmacoL (2004) 143:938–941.
   PubMed Web of Science ®Google Scholar
• SAMUEL CS, PARRY LJ, SUMMERS RJ: Physiological or pathological - a role for relaxin in the cardiovascular system? Curr. Opin. PharmacoL (2003) 3:152–158.
   Google Scholar
• LEEB-LUNDBERG LMF, MARCEAU F, MOLLER-ESTERL W, PETTIBONE DJ, ZURAW BL: International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. PharmacoL Rev. (2005) 57:27–77.
   Google Scholar
• ••A comprehensive review on the currentunderstanding of the roles of kinin receptors by acknowledged experts in the field.
   Google Scholar
• SALVINO JM, SEOANE PR, DOUTY BD et al.: Design of potent non-peptide competitive antagonists of the human bradykinin B2 receptor. J. Med. Chem. (1993) 36:2583–2584.
   PubMedGoogle Scholar
• WITHERUP KM, RANSOM RW, GRAHAM AC et al.: Martinelline and martinellic acid, novel G-protein linked receptor antagonists from the tropical plant Martinella iquitosensis (Bignoniaceae). J. Am. Chem. Soc. (1995) 117:6682–6685.
   Web of Science ®Google Scholar
• LAM YK, HENSENS OD, RANSOM R, GIACOBBE RA, POLISHOOK J, ZINK D: L-755,807, a new non-peptide bradykinin binding inhibitor from an endophytic Microsphaeropsis sp. Tetrahedron (1996) 52:1481–1486.
   Google Scholar
• EVANS BE, BOCK MG, RITTLE KE et al.: Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc. Nail. Acad. Sci. USA (1986) 83:4918–4922.
   PubMed Web of Science ®Google Scholar
• MENKE JG, BORKOWSKI JA, BIERILO KK et al.: Expression cloning of human B, bradykinin receptor. J. Biol. Chem. (1994) 269:21583–21586.
   PubMed Web of Science ®Google Scholar
• AUSTIN CE, FAUSSNER A, ROBINSON HE et al.: Stable expression of the human kinin B, receptor in chinese hamster ovary cells. Characterization of ligand binding and effector pathways. J. Biol. Chem. (1997) 272:11420–11425.
   Google Scholar
• HESS JF, BORKOWSKI JA, YOUNG GS, STRADER CD, RANSOM RW: Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem. Biophys. Res. Commun. (1992) 184:260–268.
   PubMed Web of Science ®Google Scholar
• HESS JF, BORKOWSKI JA MACNEIL T et al.: Differential pharmacology of cloned human and mouse B2 bradykinin receptor. MoL PharmacoL (1994) 45:1–8.
   Google Scholar
• MACNEIL T, BIERILO KK, MENKE JG,HESS JF: Cloning and pharmacological characterization of rabbit bradykinin B, receptor. Biochim. Biophys. Acta (1995) 1264:223–228.
   Google Scholar
• BORKOWSKI JA, RANSOM RW, SEABROOK GR et al.: Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J. Biol. Chem. (1995) 270:13706–13710.
   PubMedGoogle Scholar
• PESQUERO JB, ARAUJO RC, HEPPENSTALL PA et al.: Hypoalgesia and altered inflammatory responses in mice lacking kinin B, receptors. Proc. Natl. Acad. Sci. USA (2000) 97:8140–8145.
   PubMed Web of Science ®Google Scholar
• HOWL J, PAYNE SJ: Bradykinin receptors as a therapeutic target. Expert Opin. Ther. Targets (2003) 7:277–285.
   PubMed Web of Science ®Google Scholar
• BOCK MG, LONGMORE J: Bradykinin antagonists: new opportunities. Curr. Opin. Chem. Biol. (2000) 4:401–406.
   PubMed Web of Science ®Google Scholar
• HEITSCH H: Non-peptide antagonists and agonists of the bradykinin B2 receptor. Curr. Med. Chem. (2002) 9:913–928.
   PubMed Web of Science ®Google Scholar
• PERKINS MN: The development of bradykinin antagonists as therapeutic agents. In: Pain. Bountra C, Munglani R, Schmidt WK (Eds), Marcel Dekker, NY, USA (2003) 539–548.
   Google Scholar
• BOCK MG, HESS JF, PETTIBONE DJ: Bradykinin-1 receptor antagonists. In: Annual Reports in Medicinal Chemistry. Doherty AM (Ed.), Elsevier, USA (2003) 38:111–120.
   Google Scholar
• MARCEAU F, REGOLI D: Bradykinin receptor ligands: therapeutic perspectives. Nat. Rev., Drug Discovery (2004) 3:845–852.
   PubMed Web of Science ®Google Scholar
• CALIXTO JB, MEDEIROS R, FERNANDES ES, FERREIRA J, CABRINI DA, CAMPOS MM: Kinin B, receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br. J. PharmacoL (2004) 143:803–818.
   PubMed Web of Science ®Google Scholar
• HUANG HM, LIN TA, SUN GY, GIBSON GE: Increased inosito1-1,4,5-trisphosphate accumulation correlates with an upregulation of bradykinin receptors in Alzheimer's disease. J. Neurochem. (1995) 64:761–766.
   Google Scholar
• STEWART JM: Bradykinin antagonists as anti-cancer agents. Cuff. Pharm. Design (2003) 9:2036–2042.
   PubMed Web of Science ®Google Scholar
• HEITSCH H: The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease. Expert Opin. Investig Drugs (2003) 12:759–770.
   PubMed Web of Science ®Google Scholar
• •Very good recent review on application of B2 agonists.
   Google Scholar
• BORLONGAN CV, EMERICH DF: Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res. Bull. (2003) 60:297–306.
   PubMed Web of Science ®Google Scholar
• ALTAMURA M, MEINI S, QUARTARA L, MAGGI CA: Nonpeptide antagonists for kinin receptors. Regulatory Peptides (1999) 80:13–26.
   Google Scholar
• DZIADULEWICZ EK: Bradykinin B2 receptor antagonists for the treatment of pain. In: Annual Reports in Medicinal Chemistry Doherty AM (Ed.), Elsevier, USA (2004) 39:113–124.
   Google Scholar
• SALVINO JM, SEOANE PR, DOLLE RE: Conformational analysis of bradykinin by annealed molecular dynamics and comparison to NMR derived conformations. J. Comput. Chem. (1993) 14:438 444.
   Google Scholar
• SAWUTZ DG, SALVINO JM, DOLLE RE, SEOANE PR, FARMER SG: Pharmacology and structure activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338. Can. J. PhysioL PharmacoL (1995) 73:805–811.
   Google Scholar
• DANKWARDT SM, FERLA S, KRSTENANSKY JL, BHAKTA S, OSTRELICH H, JARNAGIN K: Nonpeptide bradykinin antagonist analogs based on a model of a Sterling Winthrop nonpeptide bradykinin antagonist overlapped with cyclic hexapeptide bradykinin antagonist peptides. Bioorg. Med. Chem. Lett. (1997) 7:1921–1926.
   Google Scholar
• SHAW KR, HUTCHISON AJ: Rapid identification and optimization of small molecule agonists and antagonists for novel targets: general considerations and specific examples. Abstracts of Papers, 220th American Chemical Society National Meeting. Washington DC, USA (2000) MEDI 321.
   Google Scholar
• DZIADULEWICZ EK, BROWN MC, DUNSTAN AR, LEE W, SAID NB, GARRATT PJ: The design of non-peptide human bradykinin B2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold. Bioorg Med. Chem. Lett. (1999) 9:463–468.
   PubMedGoogle Scholar
• MARCEAU F, HOULE S, BOUTHILLIER J, SAID NB, GARRATT PJ, DZIADULEWICZ EK: Effects of two novel non-peptide antagonists at the rabbit bradykinin B2 receptor. Peptides (2001) 22:1397–1402.
   Google Scholar
• ARTIS DR, BROTHERTON-PLEISS C, PEASE JH et al.: Structure-based design of six novel classes of nonpeptide antagonists of the bradykinin B2 receptor. Bioorg. Med. Chem. Lett. (2000) 10:2421–2425.
   Google Scholar
• GOODFELLOW VS, LAUDEMAN CP, GERRITY JI et al.: Rationally designed non-peptides: variously substituted piperazine libraries for the discovery of bradykinin antagonists and other G-protein-coupled receptor ligands. MoL Diversity (1996) 2:97–102.
   Google Scholar
• TOMASZEWSKI M: Discovery of pain targets - GPCR target class approach. Drugs Fut. (2004) 29(Supp/. A):52.
   Google Scholar
• ARAMORI I, ZENKOH J, MORIKAWA N et al.: Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657. MoL PharmacoL (1997) 51:171–176.
   PubMed Web of Science ®Google Scholar
• ABE Y, KAYAKIRI H, SATOH S et al.: A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man. J. Med. Chem. (1998) 41:4053–4061.
   Google Scholar
• ABE Y, KAYAKIRI H, SATOH S et al.: A novel class of orally active non-peptide bradykinin 132 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety. J. Med. Chem. (1998) 41:4062–4079.
   Google Scholar
• ABE Y, KAYAKIRI H, SATOH S et al.: A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework. J. Med. Chem. (1998) 41:564–578.
   Google Scholar
• HOYER D, AWAD MMA, SALVINO JM et al.: ACE inhibitors as a template for the design of bradykinin B2 receptor antagonists. Bioorg Med. Chem. Lett. (1995) 5:367–370.
   Google Scholar
• ASANO M, HATORI C, INAMURA N et al.: Effects of a nonpeptide bradykinin B2 receptor antagonist, FR167344, on different in vivo animal models of inflammation. Br. PharmacoL (1997) 122:1436–1440.
   PubMedGoogle Scholar
• ASANO M, INAMURA N, HATORI C et al.: The identification of an orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657. Br. J. PharmacoL (1997) 120:617–624.
   PubMed Web of Science ®Google Scholar
• SAWADA Y, KAYAKIRI H, ABE Yet al.: A new series of highly potent non-peptide bradykinin B2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solubility and new insights into species difference. J. Med. Chem. (2004) 47:1617–1630.
   Google Scholar
• SAWADA Y, KAYAKIRI H, ABE Yet al.: A new class of nonpeptide bradykinin B2 receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/ antagonist profile. J. Med. Chem. (2004) 47:2667–2677.
   Google Scholar
• HOCK FJ, WIRTH K, ALBUS U et al.: HOE 140, a new potent and long acting bradykinin antagonist: in vitro studies. Br. J. PharmacoL (1991) 102:769–773.
   PubMed Web of Science ®Google Scholar
• WIRTH K, HOCK FJ, ALBUS U et al.: HOE 140, a new potent and long acting bradykinin antagonist: in vivo studies. Br. J. PharmacoL (1991) 102:774–777.
   PubMed Web of Science ®Google Scholar
• PRUNEAU D, LUCCARINI JM, FOUCHET C et aL: LF 16.0335, a novel potent and selective nonpeptide antagonist of the human bradykinin B2 receptor. Br. J. PharmacoL (1998) 125:365–372.
   Google Scholar
• PRUNEAU D, LUCCARINI JM, FOUCHET C et al.: In vitro and in vivo effects of the new nonpeptide bradykinin B2 receptor antagonist, LF 16-0335C, on guinea-pig and rat kinin receptors. Fundam. Clin. PharmacoL (1999) 13:75–83.
   Google Scholar
• PRUNEAU D, PAQUET JL, LUCCARINI JM et al.: Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. Immunopharmacology (1999) 43:187–194.
   PubMedGoogle Scholar
• HEITSCH H, WAGNER A, SCHOLKENS BA, WIRTH K: Novel series of 0-substituted 8-quinolines and 4-benzothiazoles as potent antagonists of the bradykinin B2 receptors. Bioorg Med. Chem. Lett. (1999) 9:327–332.
   Google Scholar
• YOUNGMAN MA, CARSON JR, LEE JS et al.: Synthesis and structure-activity relationships of aroylpyrrole alkylamide bradykinin (B2) antagonists. Bioorg Med. Chem. Lett. (2003) 13:1341–1344.
   Google Scholar
• LEE J, REYNOLDS C, JETTER MC et al.: Design and synthesis of novel pyrrolidine-containing bradykinin antagonists. Bioorg. Med. Chem. Lett. (2003) 13:1879–1882.
   Google Scholar
• DZIADULEWICZ EK, RITCHIE TJ, HALLETT A et al.: 1-(2-Nitropheny1)-thiosemicarbazides: a novel class of potent, orally active non-peptide antagonist for the bradykinin B2 receptor. J. Med. Chem. (2000) 43:769–771.
   Google Scholar
• BURGESS GM, PERKINS MN, RANG HP et al.: Bradyzide, a potent non-peptide B2 bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br. J. PharmacoL (2000) 129:77–86.
   PubMed Web of Science ®Google Scholar
• DZIADULEWICZ EK, RITCHIE TJ, HALLETT A et al.: Non-peptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists. J. Med. Chem. (2002) 45:2160–2172.
   Google Scholar
• MARCEAU F, FORTIN JP, MOPJSSEIIh G, DZIADULEWICZ EK: A non-peptide antagonist unusually selective for the human form of the bradykinin B2 receptor. Int. ImmunopharmacoL (2003) 3:1529–1536.
   Google Scholar
• ARAMORI I, ZENKOH J, MORIKAWA N et al.: Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor. MoL PharmacoL (1997) 52:16–20.
   PubMed Web of Science ®Google Scholar
• ASANO M, HATORI C, SAWAI H et al.: Pharmacological characterization of a non-peptide bradykinin B2 receptor antagonist, FR165649, and agonist, FR190997. Br. J. PharmacoL (1998) 124:441–446.
   Google Scholar
• GOBEIL F JR, MONTAGNE M, INAMURA N, REGOLI D: Characterization of non-peptide bradykinin B2 receptor agonist (FR 190997) and antagonist (FR 173657). ImmunopharmacoL (1999) 43:179–185.
   Google Scholar
• SAWADA Y, KAYAKIRI H, ABE Yet al.: Discovery of the first non-peptide full agonists for the human bradykinin B2 receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks. J. Med. Chem. (2004) 47:2853–2863.
   Google Scholar
• BELLUCCI F, MEINI S, CUCCHI P et al.: A different molecular interaction of bradykinin and the synthetic agonist FR 190997 with the human B2 receptor: evidence from mutational analysis. Br. J. PharmacoL (2003) 140:500–506.
   Google Scholar
• MARCEAU F: A possible common pharmacophore in the non-peptide antagonists of the bradykinin B, receptor. Trends PharmacoL Sci. (2005) 26:116–118.
   Google Scholar
• GOUGAT J, FERRARI B, SARRAN L et al.: 5512240612 R2R)-2-1((3R)-3-(1,3-benzodioxo1-5-y1)-3-1[(6-methoxy-2-naphthypsulfonyl]aminolpropanoyDamino] -3-(4-1[(2R,65)-2,6-dimethylpiperidinyl]methyllpheny1)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B, receptor: biochemical and pharmacological characterization. J. PharmacoL Exp. Ther. (2004) 309:661–669.
   PubMed Web of Science ®Google Scholar
• RITCHIE TJ, DZIADULEWICZ EK, CULSHAW AJ et al.: Potent and orally bioavailable non-peptide antagonists at the human bradykinin B, receptor based on a 2-alkylamino-5-sulfamoylbenzamide core. J. Med. Chem. (2004) 47:4642–4644.
   PubMed Web of Science ®Google Scholar
• FOX A, KAUR S, LI B et al.: Antihyperalgesic activity of a novel nonpeptide bradykinin B, receptor antagonist in transgenic mice expressing the human B, receptor. Br. J. PharmacoL (2005) 144:889-899. Reports creation of hBiR 'knock-in' mouse, allowing in vivo study of a novel non-peptide BiR antagonist which is otherwise inactive at rodent RiRs.
   Google Scholar
• SU D-S, MARKOWITZ MK, DIPARDO RM et al.: Discovery of a potent, non-peptide bradykinin B1 receptor antagonist. J. Am. Chem. Soc. (2003) 125:7516–7517.
   Google Scholar
• SU D-S, MARKOWITZ MK, MURPHY KL et al.: Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies. Bioorg. Med. Chem. Lett. (2004) 14:6045–6048.
   Google Scholar
• MORISSETTE G, FORTIN J-P, OTIS S,BOUTHILLIER J, MARCEAU F: A novel non-peptide antagonist of the kinin B1 receptor: effects at the rabbit receptor. PharmacoL Exp. Ther (2004) 311:1121–1130.
   Google Scholar
• RANSOM RW, HARRELL CM, REISS DR et al.: Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist. Eur. j PharmacoL (2004) 499:77–84.
   Google Scholar
• HORLICK RA, OHLMEYER MH, STROKE IL et al.: Small molecule antagonists of the bradykinin B1 receptor. ImmunopharmacoL (1999) 43:169–177.
   PubMed Web of Science ®Google Scholar
• KUDUK SD, NG C, FENG D-M et al.: 2,3-Diaminopyridine bradykinin B1 receptor antagonists. J. Med. Chem. (2004) 47:6439–6442.
   Google Scholar
• WOOD MR, KIM JJ, HAN W et ed.: Benzodiazepines as potent and selective bradykinin B1 antagonists. J. Med. Chem. (2003) 46:1803-1806. Patents
   Google Scholar